for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Prothena Corporation PLC

PRTA.OQ

Latest Trade

8.37USD

Change

-0.14(-1.65%)

Volume

493,176

Today's Range

8.18

 - 

8.82

52 Week Range

6.71

 - 

14.77

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
8.51
Open
8.49
Volume
493,176
3M AVG Volume
4.01
Today's High
8.82
Today's Low
8.18
52 Week High
14.77
52 Week Low
6.71
Shares Out (MIL)
39.90
Market Cap (MIL)
339.52
Forward P/E
-4.34
Dividend (Yield %)
--

Next Event

Q3 2019 Prothena Corporation PLC Earnings Release

Latest Developments

More

EcoR1 Capital LLC Reports A 23.6% Stake In Prothena Corporation As Of Aug. 23

Prothena Reports Q2 2019 Results

Prothena Reports Q2 2019 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Prothena Corporation PLC

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.

Industry

Biotechnology & Drugs

Contact Info

Dublin 1, 25-28 North Wall Quay

+353.1.2362500

http://www.prothena.com/

Executive Leadership

Lars G. Ekman

Independent Chairman of the Board

Gene G Kinney

President, Chief Executive Officer, Director

Tran B. Nguyen

Chief Financial Officer, Chief Operating Officer

Karin L. Walker

Chief Accounting Officer, Controller

Wagner M. Zago

Chief Scientific Officer

Key Stats

2.88 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-4.660

2017

-4.070

2018

-3.930

2019(E)

-1.961
Price To Earnings (TTM)
--
Price To Sales (TTM)
423.34
Price To Book (MRQ)
1.12
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-17.60
Return on Equity (TTM)
-16.32

Latest News

Ocado nabs spot in FTSE 100 as traditional retailers shrink

* Retailers Mothercare and Moss Bros drop out of FTSE All-Share

BRIEF-Prothena Reports Q1 Loss Per Share $1.26

* PROTHENA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES RESEARCH AND DEVELOPMENT UPDATE

BRIEF-Prothena Corp Reports Q1 Loss Per Share $1.26

* PROTHENA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES RESEARCH AND DEVELOPMENT UPDATE

Woodford-backed biotech Prothena plunges as key drug fails

Shares in Prothena <PRTA.O>, a biotech company backed by British investor Neil Woodford, plunged 70 percent on Monday after its main drug for treating a rare disease called AL amyloidosis failed in a crucial clinical trial.

PRESS DIGEST- British Business - April 24

The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.

BRIEF-Woodford Investment Says Will Be Working With Prothena Corp On Its Strategy Beyond Its Pronto Trial Investigating NEOd001 In Al Amyloidosis

* WOODFORD INVESTMENT MANAGEMENT SAYS WILL BE WORKING WITH PROTHENA CORP ON ITS STRATEGY BEYOND ITS PRONTO TRIAL INVESTIGATING NEOD001 IN AL AMYLOIDOSIS Source text: (http://bit.ly/2HRH9mk) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Prothena Discontinues Development Of NEOD001 For Al Amyloidosis

* PROTHENA DISCONTINUES DEVELOPMENT OF NEOD001 FOR AL AMYLOIDOSIS

BRIEF-Prothena Announces Global Neuroscience Research & Development Collaboration With Celgene

* PROTHENA ANNOUNCES GLOBAL NEUROSCIENCE RESEARCH & DEVELOPMENT COLLABORATION WITH CELGENE FOR NOVEL THERAPIES FOR PATIENTS WITH NEURODEGENERATIVE DISEASES

BRIEF-Prothena Corp Files For Potential Stock Shelf Offering

* PROTHENA CORPORATION PLC FILES FOR POTENTIAL STOCK SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2oyv9Nv) Further company coverage:

BRIEF-Prothena Q4 Loss Per Share $1.24

* PROTHENA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS, AND PROVIDES FINANCIAL GUIDANCE AND RESEARCH AND DEVELOPMENT UPDATE

BRIEF-Prothena Q4 Loss Per Share $1.24

* PROTHENA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS, AND PROVIDES FINANCIAL GUIDANCE AND RESEARCH AND DEVELOPMENT UPDATE

Short seller Kerrisdale targets Woodford-backed Prothena

Hedge fund Kerrisdale Capital has taken a short position in drugmaker Prothena <PRTA.O>, a company backed by UK investor Neil Woodford, calling it "the next big biotech blowup".

PRESS DIGEST- British Business - Nov 9

Nov 9 - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.

BRIEF-Kerrisdale Capital reveals short position in Prothena Corp

* Kerrisdale Capital reveals short position in Prothena Corp, says Prothena’s "lead asset, NEOD001, will fail its ongoing phase 2B and phase 3 trials" Further company coverage:

Woodford-backed Prothena targeted by short seller Kerrisdale

Hedge fund Kerrisdale Capital has taken a short position on drugmaker Prothena, a company backed by UK investor Neil Woodford, calling it "the next big biotech blowup".

BRIEF-Prothena reports third quarter financial results

* Prothena reports third quarter 2017 financial results and provides research and development update

BRIEF-Prothena reports Q3 loss per share $1.37

* Prothena reports third quarter 2017 financial results and provides research and development update

BRIEF-Prothena reports results from phase 1b multiple ascending dose study of PRX003 in patients with Psoriasis

* Prothena reports results from phase 1b multiple ascending dose study of PRX003 in patients with psoriasis

BRIEF-Prothena Q2 loss per share $0.46

* Prothena reports second quarter 2017 financial results and provides research and development update

BRIEF-Prothena reports Q2 loss per share $0.46

* Prothena reports second quarter 2017 financial results and provides research and development update

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up